Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 55 of 116

  1. Iniparib

    Sanofi Pasteur

    Breast Cancer, Metastatic

    phase 2 small molecule completed

    1 trial

  2. Injection of humanized nerve growth factor (NGF) antibody

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Cancer Pain

    phase 2 small molecule active

    1 trial

  3. Inotuzumab Ozogamicin±Donor Lymphocyte Infusion

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Acute

    phase 2 small molecule active

    1 trial

  4. Inotuzumab ozogamicin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  5. Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

    The George Institute

    Ovarian Cancer

    phase 2 other active

    1 trial

  6. Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells

    The First People's Hospital of Lianyungang

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  7. Intermittent PD-1/PD-L1 ICI + VEGFR-TKI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Renal Cell Carcinoma (RCC)

    phase 2 small molecule active

    1 trial

  8. Intismeran autogene

    Merck KGaA, Darmstadt, Germany

    Malignant Melanoma

    phase 2 mab active

    1 trial

  9. Intravenous esketamine using Dixon's up-and-down sequential method

    The First People's Hospital of Lianyungang

    Hepatic Neoplasm

    phase 2 small molecule active

    1 trial

  10. Iodine-124

    United Therapeutics Europe Ltd

    Thyroid Cancer

    phase 2 small molecule active

    1 trial

  11. Iomab-B

    Actinium Pharmaceuticals

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  12. Iparomlimab and Tuvonralimab Injection (QL1706)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  13. Iparomlimab and Tuvonralimab Injection (QL1706)

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  14. Iparomlimab and Tuvonralimab Injection in combination with TFOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. Iparomlimab and Tuvonralimab combined with lenvatinib and SOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. Iparomlimab/Tuvonralimab

    Chinese University of Hong Kong

    LOCALLY ADVANCED CERVICAL CANCERS

    phase 2 small molecule active

    1 trial

  17. Iparomlimab/Tuvonralimab

    The First People's Hospital of Lianyungang

    Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  18. Ipilimumab

    United Therapeutics Europe Ltd

    BCLC Stage B Hepatocellular Carcinoma

    phase 2 mab terminated

    1 trial

  19. Ipilimumab

    United Therapeutics Europe Ltd

    Locally Advanced Clear Cell Renal Cell Carcinoma

    phase 2 mab active

    1 trial

  20. Irinotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Irinotecan Liposome

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  22. Irofulven

    Allarity Therapeutics

    Metastatic Castration-Resistant Prostate Cancer Patients

    phase 2 small molecule completed

    1 trial

  23. Irosustat

    United Therapeutics Europe Ltd

    Breast Neoplasms

    phase 2 small molecule terminated

    1 trial

  24. Ivaltinostat

    CG Oncology

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  25. Ivonescimab

    Summit Therapeutics

    Metastatic Esophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  26. Ivonescimab

    Summit Therapeutics

    Stomach Cancer Stage IV

    phase 2 small molecule active

    1 trial

  27. Ivonescimab

    Summit Therapeutics

    Salivary Gland Cancer

    phase 2 small molecule active

    1 trial

  28. Ivonescimab

    Summit Therapeutics

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    3 trials

  29. Ivonescimab

    Summit Therapeutics

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  30. Ivonescimab

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  31. Ivonescimab

    Summit Therapeutics

    Leiomyosarcoma

    phase 2 small molecule active

    1 trial

  32. Ivonescimab

    Summit Therapeutics

    Thymus Carcinoma

    phase 2 mab active

    1 trial

  33. Ivonescimab

    Summit Therapeutics

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  34. Ivonescimab

    Summit Therapeutics

    Advanced Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  35. Ivonescimab

    Summit Therapeutics

    Endometrial Cancer

    phase 2 small molecule active

    1 trial

  36. Ivonescimab

    Summit Therapeutics

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  37. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Extensive Stage Lung Small Cell Cancer

    phase 2 small molecule active

    1 trial

  38. Ivonescimab 20 mg/kg

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  39. Ivonescimab combined with TP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  40. Ivosidenib combined with venetoclax and azacitidine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  41. Ixabepilone Injection

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  42. Ixazomib

    Takeda

    Mantle Cell Lymphoma

    phase 2 small molecule active

    2 trials

  43. Ixazomib

    Takeda

    Triple-Negative Breast Cancer

    phase 2 small molecule terminated

    1 trial

  44. Ixazomib

    Takeda

    Leukemia

    phase 2 small molecule terminated

    1 trial

  45. J1S-MC-JP04

    Eli Lilly Co.

    Ewings Sarcoma

    phase 2 small molecule active

    1 trial

  46. J2R-MC-YAAD

    Eli Lilly Co.

    Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

    phase 2 small molecule active

    1 trial

  47. JAB-21822

    Lacuna Pharma Pty Ltd

    advanced solid tumors with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  48. JCAR017

    Celgene Europe Limited

    Lymphoma, Non-Hodgkin

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.